- Home
- BLRX vs GSIW Comparison
BLRX vs GSIW Comparison
Compare BLRX & GSIW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BLRX
- GSIW
- Stock Information
- Founded
- BLRX 2003
- GSIW 2016
- Country
- BLRX Israel
- GSIW Hong Kong
- Employees
- BLRX N/A
- GSIW N/A
- Industry
- BLRX Biotechnology: Pharmaceutical Preparations
- GSIW
- Sector
- BLRX Health Care
- GSIW
- Exchange
- BLRX Nasdaq
- GSIW Nasdaq
- Market Cap
- BLRX 10.3M
- GSIW 8.3M
- IPO Year
- BLRX 2011
- GSIW 2023
- Fundamental
- Price
- BLRX $2.93
- GSIW $0.39
- Analyst Decision
- BLRX Buy
- GSIW
- Analyst Count
- BLRX 2
- GSIW 0
- Target Price
- BLRX $26.00
- GSIW N/A
- AVG Volume (30 Days)
- BLRX 30.2K
- GSIW 68.6K
- Earning Date
- BLRX 05-27-2025
- GSIW 12-31-2024
- Dividend Yield
- BLRX N/A
- GSIW N/A
- EPS Growth
- BLRX N/A
- GSIW N/A
- EPS
- BLRX N/A
- GSIW N/A
- Revenue
- BLRX $28,940,000.00
- GSIW $1,313,795.00
- Revenue This Year
- BLRX N/A
- GSIW N/A
- Revenue Next Year
- BLRX N/A
- GSIW N/A
- P/E Ratio
- BLRX N/A
- GSIW N/A
- Revenue Growth
- BLRX 502.92
- GSIW N/A
- 52 Week Low
- BLRX $2.30
- GSIW $0.35
- 52 Week High
- BLRX $35.60
- GSIW $12.30
- Technical
- Relative Strength Index (RSI)
- BLRX 48.07
- GSIW 43.90
- Support Level
- BLRX $2.30
- GSIW $0.35
- Resistance Level
- BLRX $3.09
- GSIW $0.43
- Average True Range (ATR)
- BLRX 0.22
- GSIW 0.04
- MACD
- BLRX 0.06
- GSIW -0.00
- Stochastic Oscillator
- BLRX 79.33
- GSIW 36.67
About BLRX BioLineRx Ltd.
BioLine Rx Ltd is a commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has an off-strategy, legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.
About GSIW Garden Stage Limited
Garden Stage Ltd is a Hong Kong-based financial services provider principally engaged in the provision of placing and underwriting services; securities dealing and brokerage services; and asset management services. Its business is carried out through its wholly owned Operating Subsidiaries: a) I Win Securities, which is licensed to conduct Type 1 (dealing in securities) regulated activities under the SFO in Hong Kong, and b) I Win Asset Management, which is licensed to conduct Type 4 (advising on securities) and Type 9 (asset management) regulated activities under the SFO in Hong Kong.